Accenture and Salesforce Collaborate to Help Life Sciences Companies Create Differentiation with Data and AI

To help life sciences companies create sustainable value and drive growth, Accenture (NYSE: ACN) and Salesforce (NYSE: CRM) are investing in the development of Salesforce Life Sciences Cloud including new innovations, assets and accelerators, powered by data and artificial intelligence (AI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231106302240/en/

To help life sciences companies create sustainable value and drive growth, Accenture and Salesforce are investing in the development of Salesforce Life Sciences Cloud including new innovations, assets and accelerators, powered by data and artificial intelligence (AI). (Graphic: Business Wire)

To help life sciences companies create sustainable value and drive growth, Accenture and Salesforce are investing in the development of Salesforce Life Sciences Cloud including new innovations, assets and accelerators, powered by data and artificial intelligence (AI). (Graphic: Business Wire)

Building on the recently announced Accenture and Salesforce generative AI collaboration, the companies will leverage their joint generative AI acceleration hub to develop new solutions and use cases for Salesforce Life Sciences Cloud. The companies will also use Salesforce Data Cloud and Einstein AI, Salesforce's AI technology, to help increase productivity and transform healthcare professional and patient experiences.

“The rapid pace of science and technology advancements is making treatment decisions more complex,” said Emma McGuigan, senior managing director and Enterprise & Industry Technologies lead at Accenture. “Data and AI will drive differentiation around how life sciences organizations engage with their customers. Together with Salesforce, we can help organizations establish a digital foundation to support omni-channel experiences across sales, service and marketing with data and intelligence at the core.”

The accelerated adoption of data and analytics capabilities to fuel decisions and operations is a top investment priority for 58% of life sciences companies, according to Accenture Research.

“As we build the next generation Life Sciences Platform, Accenture is partnering with our teams to provide its deep industry expertise," said Amit Khanna, SVP & GM, Health and Life Sciences at Salesforce. “Accenture’s deep understanding of the pharma and medtech spaces and their current work to transform patient experiences will help us create new innovation for life sciences companies and in the new development of Salesforce Life Sciences Cloud.”

Accenture and Salesforce have worked with Cencora (formerly AmerisourceBergen), a global pharmaceutical solutions provider that offers integrated support, including patient services, across the pharmaceutical development and commercialization journey. With Life Sciences Cloud, the companies will help Cencora utilize rich data and insights to modernize patient engagement with a digital-first capability at scale.

“Cencora is committed to leveraging new and emerging technologies, like generative AI, to deliver solutions that reduce potential barriers along the treatment journey and meet the needs of our biopharma partners, healthcare providers and the patients they serve,” said Shannon Coven, senior vice president, Data & Platforms for Global Pharma Services at Cencora. “Together with Accenture and Salesforce, we are harnessing the power of data and AI to help improve outcomes and enhance the patient care experience.”

Together, Accenture and Salesforce have already developed assets and accelerators including:

  • A patient services Health Cloud assessment framework, which evaluates legacy pharma patient services solutions to generate insights and a value case for Salesforce Life Sciences Cloud.
  • A pharmaceutical Data Cloud and Einstein AI accelerator, which provides a holistic view of provider and patient data, using the power of generative AI. It enables greater impact by suggesting the most important messages to be delivered to the patient during the next interaction.

Accenture will continue to develop complementary tools and methodologies to help clients test and pilot the new capabilities of Salesforce Life Sciences Cloud.

About Accenture

Accenture is a leading global professional services company that helps the world’s leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 733,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. We are uniquely able to deliver tangible outcomes because of our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song. These capabilities, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at www.accenture.com.

About Salesforce

Salesforce empowers companies of every size and industry to connect with their customers through the power of data + AI + CRM + trust. For more information about Salesforce (NYSE: CRM), visit: www.salesforce.com.

Copyright © 2023 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.

Salesforce, Life Sciences Cloud, Health Cloud, Data Cloud, Einstein and others are among the trademarks of Salesforce, Inc.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.